Balancing Affordability, Access, and Sustainability
Published on April 16, 2026
Drug pricing in Canada is not determined by a single factor, it is the result of a complex, globally influenced system that balances affordability for patients with the need to sustain a reliable pharmaceutical supply chain. At the centre of this system is the Patented Medicine Prices Review Board (PMPRB), a federal body that ensures the prices of patented medicines sold in Canada are not excessive while monitoring broader pricing trends. For Vital, drug pricing is more than a regulatory issue, it is a core supply chain consideration that directly impacts access, availability, and long-term system resilience.
Canada in a Global Pricing Environment
Pharmaceutical pricing operates within a global marketplace, where manufacturers set prices across multiple countries based on market size, regulation, and reimbursement systems.
Canada’s approach is unique:
- Prices are reviewed, not set, by regulators
- Benchmarking often considers international price comparisons
- Pricing must align with both clinical value and existing therapies
This positions Canada as a mid-sized, highly regulated market, dependent on global pricing strategies but focused on domestic affordability.
The PMPRB plays a critical role in maintaining balance within the system.
It prevents excessive pricing of patented medicines; monitoring market trends, including pricing, utilization, and R&D investment; and supporting evidence-based decision-making for payers and policymakers. Importantly, the PMPRB does not directly set prices. Instead, it establishes thresholds and conducts reviews, intervening when prices exceed acceptable limits. Recent reforms, including updated Guidelines effective in 2026, introduce a more structured review process that compares prices across countries and similar treatments.
Why Drug Pricing Matters to the Supply Chain
Drug pricing is often viewed through an affordability lens—but it also has direct implications for supply chain performance.
Market Attractiveness and Supply Availability
Pricing levels influence whether manufacturers prioritize Canada for product launches and supply allocation. Lower prices relative to other markets can affect inventory levels, allocation decisions, and risk of shortages.
Why Drug Pricing Matters to the Supply Chain
Drug pricing is often viewed through an affordability lens—but it also has direct implications for supply chain performance.
Market Attractiveness and Supply Availability
Pricing levels influence whether manufacturers prioritize Canada for product launches and supply allocation. Lower prices relative to other markets can affect inventory levels, allocation decisions, and risk of shortages.
Global Flow of Medicines and System Sustainability
Because medicines move across borders, pricing disparities can create cross-market pressures, including parallel trade or importation risks and shifts in supply toward higher-priced markets. A well-functioning pricing framework helps ensure long-term access to innovative therapies, predictable supply chain operations, and balanced healthcare spending .
A System Designed for Balance
Canada’s pharmaceutical pricing system is designed to achieve three core outcomes:
- Protect Patients: Ensure medicines remain affordable and accessible
- Support Sustainability: Enable stable, predictable supply across the country
- Align with Global Markets: Reflect international pricing realities without overexposing domestic supply
The PMPRB contributes to this balance by acting as a check on pricing while providing transparency into market trends.
Our perspective
Vital views drug pricing as a critical supply chain lever, supporting fair and predictable policies that safeguard Canada’s access to medicines. By balancing cost with downstream impacts on supply and availability, we ensure pricing decisions prioritize long-term patient outcomes.